8-K
ACCURAY INC (ARAY)
UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
| Date of Report (Date of earliest event reported): February 05, 2025 |
|---|
ACCURAY INCORPORATED
(Exact name of Registrant as Specified in Its Charter)
| Delaware | 001-33301 | 20-8370041 |
|---|---|---|
| (State or Other Jurisdiction<br>of Incorporation) | (Commission File Number) | (IRS Employer<br>Identification No.) |
| 1240 Deming Way | ||
| Madison, Wisconsin | 53717-1954 | |
| (Address of Principal Executive Offices) | (Zip Code) | |
| Registrant’s Telephone Number, Including Area Code: 608 824-2800 | ||
| --- |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading<br>Symbol(s) | Name of each exchange on which registered |
|---|---|---|
| Common Stock, $0.001 par value per share | ARAY | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On February 5, 2025, the Company issued a press release announcing its financial results for the second quarter ended December 31, 2024. A copy of the Company’s press release dated February 5, 2025, titled “Accuray Reports Fiscal 2025 Second Quarter Financial Results” is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
The foregoing information (including the exhibit hereto) is being furnished under “Item 2.02 Results of Operations and Financial Condition” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), except as shall be expressly set forth by specific reference in such filing.
Item 7.01 Regulation FD Disclosure.
Spokespersons of the Company plan to present the information in the presentation attached hereto as Exhibit 99.2 to analysts and investors from time to time on or after February 5, 2025. The presentation will be available on the Company’s Investor Relations website at: http://investors.accuray.com.
The furnishing of the attached presentation is not an admission as to the materiality of any information therein. The information contained in the presentation is summary information that is intended to be considered in the context of more complete information included in the Company’s filings with the U.S. Securities and Exchange Commission and other public announcements that the Company has made and may make from time to time by press release or otherwise. The Company undertakes no duty or obligation to update or revise the information contained in this report. For important information about forward looking statements, see the slide titled “Forward-Looking Statements” in Exhibit 99.2 attached hereto.
The information set forth under Item 2.02 of this Current Report on Form 8-K is incorporated by reference into this Item 7.01.
The information contained in this Item 7.01 disclosure, including Exhibit 99.1 and Exhibit 99.2, is furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for the purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that Section, nor shall it be incorporated by reference into a filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. | Description |
|---|---|
| 99.1 | Press release dated February 5, 2025, titled “Accuray Reports Fiscal 2025 Second Quarter Financial Results” |
| 99.2 | Accuray Second Quarter Fiscal 2025 Earnings Call Presentation |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| ACCURAY INCORPORATED | |||
|---|---|---|---|
| Date: | February 5, 2025 | By: | /s/ Ali Pervaiz |
| Ali Pervaiz<br>Senior Vice President & Chief Financial Officer |
EX-99.1
Exhibit 99.1
Accuray Reports Strong Fiscal 2025 Second Quarter Financial Results & Raises Guidance
MADISON, Wis, February 5, 2025 — Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the second quarter ended December 31, 2024.
Key Fiscal Q2 Highlights:
- Strong second quarter and first half results; raising fiscal year 2025 guidance
- Total net revenue was $116.2 million, an increase of 8 percent year-over-year
- Net income was $2.5 million compared to a net loss of $9.6 million in the prior year period
- Adjusted EBITDA was $9.6 million compared to $2.0 million in the prior year period
“Our strong Q2 performance reflects outstanding execution of our strategies of advancing radiotherapy care, expanding patient access and improving margin performance of the business. We continue to see growing demand for our solutions from our increased commercial presence particularly in fast-growing emerging markets evidenced by the strong momentum in Tomo C System deliveries this quarter, as well as breakthrough wins of our new Helix system, following CE mark in the first fiscal quarter,” said Suzanne Winter, president and CEO of Accuray. “Our continued innovation in product and service offerings are helping close the gaps to cancer care and expand on the curative power of radiation therapy to improve as many lives as possible.”
Fiscal Second Quarter Results
Total net revenue in the second quarter of fiscal 2025 increased to $116.2 million, or an increase of 8 percent, from $107.2 million in the prior fiscal year second quarter. Product revenue in the second quarter of fiscal 2025 increased to $61.2 million, or an increase of 19 percent, from $51.5 million in the prior fiscal year second quarter. Service revenue in the second quarter of fiscal 2025 decreased to $55.0 million, or a decrease of 1 percent, from $55.7 million in the prior fiscal year second quarter.
Total gross profit in the second quarter of fiscal 2025 increased to $41.9 million, or 36.1 percent of total net revenue, compared to a total gross profit of $35.9 million, or 33.5 percent of total net revenue, in the prior fiscal year second quarter.
Operating expenses in the second quarter of fiscal 2025 decreased to $37.2 million, or a decrease of 7 percent, from $39.9 million in the prior fiscal year second quarter.
Net income in the second quarter of fiscal 2025 was $2.5 million, or $0.03 per share, compared to a net loss of $9.6 million, or $0.10 per share, in the prior fiscal year second quarter. Adjusted EBITDA in the second quarter of fiscal 2025 was $9.6 million, compared to $2.0 million in the prior fiscal year second quarter.
Gross product orders in the second quarter of fiscal 2025 decreased to $76.8 million from $93.9 million in the prior fiscal year second quarter. The book to bill ratio was 1.3 in the second quarter of fiscal 2025, compared to a book to bill ratio of 1.8 in the prior fiscal year second quarter. Order backlog as of December 31, 2024 was $463.1 million, which is approximately 6 percent lower than at the end of the prior fiscal year second quarter.
Cash, cash equivalents, and short-term restricted cash were $64.0 million as of December 31, 2024, an increase of $4.3 million from September 30, 2024 and a $5.0 million decrease from June 30, 2024.
Fiscal Six Months Results
Total net revenue in the first six months of fiscal 2025 increased to $217.7 million, or an increase of 3 percent, from $211.1 million in the prior fiscal year period. Product revenue in the six months of fiscal 2025 increased to $109.6 million, or an increase of 4 percent, from $104.9 million in the prior fiscal year period. Service revenue in the first six months of fiscal 2025 increased to $108.2 million, or an increase of 2%, from $106.2 million in the prior fiscal year period.
Total gross profit in the first six months of fiscal 2025 increased to $76.4 million, or 35.1 percent of total net revenue, as compared to total gross profit of $75.4 million, or 35.7 percent of total net revenue, in the prior fiscal year period.
Operating expenses in the first six months of fiscal 2025 decreased to $73.8 million, or a decrease of 4 percent, from $77.1 million in the prior fiscal year period.
Net loss in the first six months of fiscal 2025 was $1.4 million, or $0.01 per share, compared to a net loss of $12.6 million, or $0.13 per share, in the prior fiscal year period. Adjusted EBITDA in the first six months of fiscal 2025 was $12.8 million, compared to $8.5 million in the prior fiscal year period.
Gross product orders in the first six months of fiscal 2025 decreased to $132.1 million from $157.6 million in the prior fiscal year period. The book to bill ratio was 1.2 in the first six months of fiscal 2025, compared to a book to bill ratio of 1.5 in the same period in the prior fiscal year second quarter.
Fiscal Year 2025 Financial Guidance
The Company is raising guidance for fiscal year 2025 as follows:
- Total revenue is expected in the range of $463 million to $475 million.
- Adjusted EBITDA is expected in the range of $28.5 million to $31.0 million.
The Company’s guidance assumes minimal tariff impact and that the U.S. market will begin its recovery in the second half of fiscal 2025. Guidance for non-GAAP financial measures excludes depreciation and amortization, stock-based compensation, interest expense, and provision for income taxes. For more information regarding the non-GAAP financial measures discussed in this press release, please see "Use of Non-GAAP Financial Measures" below.
Conference Call Information
Accuray will host a conference call beginning at 1:30 p.m. PT/4:30 p.m. ET today to discuss results for the first quarter of fiscal 2025 as well as recent corporate developments. Conference call dial-in information is as follows:
- U.S. callers: (833) 316-0563
- International callers: (412) 317-5747
Individuals interested in listening to the live conference call via the Internet may do so by logging on to the Investor Relations section of Accuray’s website, www.accuray.com. There will be a slide presentation accompanying today’s event which can also be accessed on the company’s Investor Relations page at www.accuray.com.
In addition, a taped replay of the conference call will be available beginning approximately one hour after the call’s conclusion and will be available for seven days. The replay number is (877) 344-7529 (USA), or (412) 317-0088 (International), Conference ID: 8496951. An archived webcast will also be available on Accuray’s website until Accuray announces its results for the third quarter of fiscal 2025.
Use of Non-GAAP Financial Measures
Accuray reports its financial results in accordance with generally accepted accounting principles in the United States (“GAAP”) and the rules of the SEC. To supplement its financial statements prepared and presented in accordance with GAAP, Accuray uses certain non-GAAP financial measures, such as adjusted EBITDA.
Accuray has supplemented its GAAP net income (loss) with a non-GAAP measure of adjusted earnings before interest, taxes, depreciation, amortization, stock-based compensation, and ERP and ERP related expenditures. (“adjusted EBITDA”). The calculation of adjusted EBITDA also excludes certain non-recurring, irregular and one-time items. Management believes that this non-GAAP financial measure provides useful supplemental information to management and investors regarding the performance of the company and facilitates a meaningful comparison of results for current periods with previous operating results. A reconciliation of GAAP net income (loss) (the most directly comparable GAAP measure) to non-GAAP adjusted EBITDA is provided in the schedules below.
There are limitations in using these non-GAAP financial measures because they are not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial measures. Investors and potential investors should consider non-GAAP financial measures only in conjunction with the company’s consolidated financial statements prepared in accordance with GAAP.
About Accuray
Accuray Incorporated (Nasdaq: ARAY) is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions that are designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Madison, Wisconsin, with facilities worldwide.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to the company's guidance and future results of operations, including expectations regarding: total revenue and adjusted EBITDA; the company’s ability to execute on its strategies, invest on innovations and provide customers with products that enables them to elevate cancer care; the company's ability to benefit from advances in long-term growth and profitability drivers; the company’s ability to navigate supply chain, logistics, macroeconomic, and foreign exchange challenges; the company's ability to deliver on its strategic growth agenda and fiscal 2025 plans, ability to progress against long-term strategic goals, and ability to continue adoption and expansion of access of its technologies; the company’s ability to execute on margin and profitability expansion initiatives; expectations regarding commercial strategy and execution as well as growth opportunities; expectations regarding the company’s China joint venture and the Tomo® C System; expectations related to the amount and timing of realizing deferred margin from the company’s China joint venture; expectations with respect to strategic partnerships and collaborations; expectations related to the markets and regions in which the company operates and its ability to gain share in those markets and regions; expectations regarding new product introductions and innovations, and related regulatory submissions and approvals, including with respect to the Accuray HelixTM platform, and their effect on use and adoption of the company's products; expectations regarding orders and service business growth as well as revenue, margin and adjusted EBITDA growth; expectations regarding backlog; expectations regarding the company's capital structure and refinancing needs; expectations regarding the company’s addressable market; and the company’s ability to advance patient care and offer value to its customer. These forward-looking statements involve risks and uncertainties. If any of these risk or uncertainties materialize, or if any of the company’s assumptions prove incorrect, actual results could differ materially from the results express or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the effect of the global macroeconomic environment on the operations of the company and those of its customers and suppliers; disruptions to our supply chain, including increased logistics costs; the company's ability to achieve widespread market acceptance of its products; the company’s ability to realize the expected benefits of the China joint venture and other partnerships; risks inherent in international operations; the company's ability to maintain or increase its gross margins on product sales and services; delays in regulatory approvals or the development or release of new offerings; the company's ability to meet the covenants under its credit facilities; the company's ability to convert backlog to revenue; and such other risks identified under the heading “Risk Factors” in the company's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (the “SEC”) on November 6, 2024, and as updated periodically with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
| Aman Patel, CFA | Beth Kaplan |
|---|---|
| Investor Relations, ICR-Westwicke | Public Relations Director, Accuray |
| +1 (443) 450-4191 | +1 (408) 789-4426 |
| aman.patel@westwicke.com | bkaplan@accuray.com |
Financial Tables to Follow
Accuray Incorporated
Condensed Consolidated Statements of Operations
(in thousands, except per share data)
(Unaudited)
| Three Months Ended <br>December 31, | Six Months Ended<br>December 31, | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |||||||||
| Net revenue: | ||||||||||||
| Products | $ | 61,189 | $ | 51,538 | $ | 109,558 | $ | 104,888 | ||||
| Services | 54,985 | 55,700 | 108,161 | 106,242 | ||||||||
| Total net revenue | 116,174 | 107,238 | 217,719 | 211,130 | ||||||||
| Cost of revenue: | ||||||||||||
| Cost of products | 34,553 | 34,333 | 67,014 | 70,032 | ||||||||
| Cost of services | 39,729 | 37,003 | 74,344 | 65,703 | ||||||||
| Total cost of revenue | 74,282 | 71,336 | 141,358 | 135,735 | ||||||||
| Gross profit | 41,892 | 35,902 | 76,361 | 75,395 | ||||||||
| Operating expenses: | ||||||||||||
| Research and development | 13,644 | 15,281 | 25,760 | 29,294 | ||||||||
| Selling and marketing | 11,114 | 11,361 | 22,796 | 21,605 | ||||||||
| General and administrative | 12,427 | 13,224 | 25,247 | 26,247 | ||||||||
| Total operating expenses | 37,185 | 39,866 | 73,803 | 77,146 | ||||||||
| Income (loss) from operations | 4,707 | (3,964 | ) | 2,558 | (1,751 | ) | ||||||
| Income (loss) from equity method investment, net | 1,604 | (427 | ) | 1,532 | 4 | |||||||
| Interest expense | (2,883 | ) | (2,922 | ) | (5,838 | ) | (5,844 | ) | ||||
| Other income (expense), net | (196 | ) | (1,430 | ) | 1,651 | (2,189 | ) | |||||
| Income (loss) before provision for income taxes | 3,232 | (8,743 | ) | (97 | ) | (9,780 | ) | |||||
| Provision for income taxes | 695 | 878 | 1,320 | 2,810 | ||||||||
| Net income (loss) | $ | 2,537 | $ | (9,621 | ) | $ | (1,417 | ) | $ | (12,590 | ) | |
| Net income (loss) per share - basic | $ | 0.03 | $ | (0.10 | ) | $ | (0.01 | ) | $ | (0.13 | ) | |
| Net income (loss) per share - diluted | $ | 0.02 | $ | (0.10 | ) | $ | (0.01 | ) | $ | (0.13 | ) | |
| Weighted average common shares used in computing net income (loss) per share: | ||||||||||||
| Basic | 101,405 | 97,776 | 100,796 | 97,165 | ||||||||
| Diluted | 103,746 | 97,776 | 100,796 | 97,165 |
Accuray Incorporated
Condensed Consolidated Balance Sheets
(in thousands)
(Unaudited)
| December 31, | June 30, | |||||
|---|---|---|---|---|---|---|
| 2024 | 2024 | |||||
| Assets | ||||||
| Current assets: | ||||||
| Cash and cash equivalents | $ | 62,584 | $ | 68,570 | ||
| Restricted cash | 1,433 | 485 | ||||
| Accounts receivable, net | 87,275 | 92,001 | ||||
| Inventories, net | 148,826 | 138,324 | ||||
| Prepaid expenses and other current assets | 25,440 | 23,006 | ||||
| Deferred cost of revenue | 333 | 850 | ||||
| Total current assets | 325,891 | 323,236 | ||||
| Property and equipment, net | 26,881 | 24,774 | ||||
| Investment in joint venture | 12,837 | 9,826 | ||||
| Operating lease right-of-use assets, net | 31,716 | 33,773 | ||||
| Goodwill | 57,643 | 57,672 | ||||
| Long-term restricted cash | 1,371 | 1,337 | ||||
| Other assets | 22,043 | 18,009 | ||||
| Total assets | $ | 478,382 | $ | 468,627 | ||
| Liabilities and stockholders' equity | ||||||
| Current liabilities: | ||||||
| Accounts payable | $ | 53,991 | $ | 50,020 | ||
| Accrued compensation | 19,350 | 17,128 | ||||
| Operating lease liabilities, current | 7,518 | 6,218 | ||||
| Other accrued liabilities | 27,987 | 28,508 | ||||
| Customer advances | 12,959 | 13,988 | ||||
| Deferred revenue | 72,088 | 71,649 | ||||
| Short-term debt | 7,560 | 7,756 | ||||
| Total current liabilities | 201,453 | 195,267 | ||||
| Operating lease liabilities, non-current | 30,459 | 32,373 | ||||
| Long-term other liabilities | 6,010 | 7,389 | ||||
| Deferred revenue, non-current | 24,616 | 24,114 | ||||
| Long-term debt | 167,953 | 164,400 | ||||
| Total liabilities | 430,491 | 423,543 | ||||
| Stockholders' equity: | ||||||
| Common stock | 103 | 100 | ||||
| Additional paid-in capital | 572,287 | 566,887 | ||||
| Accumulated other comprehensive loss | (5,401 | ) | (4,222 | ) | ||
| Accumulated deficit | (519,098 | ) | (517,681 | ) | ||
| Total stockholders' equity | 47,891 | 45,084 | ||||
| Total liabilities and stockholders' equity | $ | 478,382 | $ | 468,627 |
Accuray Incorporated
Summary of Orders and Backlog
(in thousands, except book to bill ratio)
(Unaudited)
| Three Months Ended <br>December 31, | Six Months Ended<br>December 31, | |||||||
|---|---|---|---|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |||||
| Gross orders | $ | 76,762 | $ | 93,856 | $ | 132,127 | $ | 157,590 |
| Net orders | 55,639 | 54,606 | 85,295 | 86,346 | ||||
| Order backlog | 463,056 | 492,100 | 463,056 | 492,100 | ||||
| Book to bill ratio (a) | 1.3 | 1.8 | 1.2 | 1.5 |
(a) Book to bill ratio is defined as gross orders for the period divided by product revenue for the period.
Accuray Incorporated
Reconciliation of GAAP Net Loss to Adjusted EBITDA
(in thousands)
(Unaudited)
| Three Months Ended <br>December 31, | Six Months Ended<br>December 31, | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | ||||||||
| GAAP net income (loss) | $ | 2,537 | $ | (9,621 | ) | $ | (1,417 | ) | $ | (12,590 | ) |
| Depreciation and amortization (a) | 1,513 | 1,546 | 2,977 | 2,797 | |||||||
| Stock-based compensation | 2,284 | 2,314 | 4,638 | 4,706 | |||||||
| Interest expense, net (b) | 2,605 | 2,713 | 5,257 | 5,341 | |||||||
| Provision for income taxes | 695 | 878 | 1,320 | 2,810 | |||||||
| Restructuring charges | — | 2,633 | — | 2,633 | |||||||
| ERP and ERP related expenditures | — | 1,545 | — | 2,815 | |||||||
| Adjusted EBITDA | $ | 9,634 | $ | 2,008 | $ | 12,775 | $ | 8,512 |
(a) Consists of depreciation on property and equipment and amortization of intangibles.
(b) Consists of interest expense net of interest income.
Accuray Incorporated
Forward-Looking Guidance
Reconciliation of Projected GAAP Net Loss to Projected Adjusted EBITDA
(in thousands)
(Unaudited)
| Twelve Months Ending<br>June 30, 2025 | ||||||
|---|---|---|---|---|---|---|
| From | To | |||||
| GAAP net loss | $ | (4,000 | ) | $ | (1,500 | ) |
| Depreciation and amortization (a) | 6,500 | 6,500 | ||||
| Stock-based compensation | 10,000 | 10,000 | ||||
| Interest expense, net (b) | 13,000 | 13,000 | ||||
| Provision for income taxes | 3,000 | 3,000 | ||||
| Adjusted EBITDA | $ | 28,500 | $ | 31,000 |
(a) Consists of depreciation on property and equipment and amortization of intangibles.
(b) Consists of interest expense net of interest income.
Q2’FY25 Earnings Call Supplemental Presentation February 5, 2025
Forward-looking Statements This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. 2 Proprietary and Confidential Property of Accuray Safe Harbor Statement Statements in this presentation (including the oral commentary that accompanies it) that are not statements of historical fact are forward-looking statements and are subject to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this presentation relate, but are not limited, to: expectations regarding adjusted EBITDA and revenue; expectations regarding China deferred margin release; our ability to deliver on our goals, priorities, and strategic growth plans; our expectations related to the markets and regions in which we operate; expectations related to our China joint venture, including related to the Tomo-C System and margin deferral from the China joint venture; and expectations related to new product innovations and offerings as well as revenue growth and market share going forward. Forward-looking statements generally can be identified by words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “projects,” “may,” “will be,” “will continue,” and similar expressions. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from expectations. These risks and uncertainties include, but are not limited to: risks related to the effect of the global macroeconomic environment on the operations of the company and those of its customers and suppliers; disruptions to our supply chain, including increased logistics costs; the company's ability to achieve widespread market acceptance of its products; the company’s ability to realize the expected benefits of the China joint venture and other partnerships; risks inherent in international operations; the company's ability to maintain or increase its gross margins on product sales and services; delays in regulatory approvals or the development or release of new offerings; the company's ability to meet the covenants under its credit facilities; the company's ability to convert backlog to revenue and other risks identified under the heading “Risk Factors” in our annual report on Form 10-K, filed with the Securities and Exchange Commission (the “SEC”) on September 19, 2024, and as updated periodically with our other filings with the SEC. Forward-looking statements speak only as of the date the statements are made and are based on information available to Accuray at the time those statements are made and/or management’s good faith belief as of that time with respect to future events. Accuray assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not place undue reliance on any forward-looking statements. Non-GAAP Financial Measures This presentation also contains non-GAAP financial measures. Management believes that non-GAAP financial measures provide useful supplemental information to management and investors regarding the performance of the company and facilitates a more meaningful comparison of results for current periods with previous operating results. Additionally, these non-GAAP financial measures assist management in analyzing future trends, making strategic and business decisions, and establishing internal budgets and forecasts. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP measure is provided in the Appendix. Accuray has also reported certain operating results on a constant currency basis in order to facilitate period-to-period comparisons of its results without regard to the impact of foreign currency exchange rate fluctuations. Management believes disclosure of non-GAAP constant currency results is helpful to investors because it facilitates period-to-period comparisons of the company's results by increasing the transparency of the underlying performance by excluding the impact of foreign currency exchange rate fluctuations. Accuray calculates the constant currency amounts by translating local currency amounts in the current period using the same foreign translation rate used in the prior period being compared against rather than the actual exchange rate in effect during the current period. There are limitations in using these non-GAAP financial measures because they are not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial measures. Investors and potential investors should consider non-GAAP financial measures only in conjunction with the company’s consolidated financial statements prepared in accordance with GAAP. Medical Advice Disclaimer Accuray Incorporated as a medical device manufacturer cannot and does not recommend specific treatment approaches. Individual results may vary.
Highlights Strong second quarter and first half results; raising fiscal year 2025 guidance Total net revenue was $116.2 million, an increase of 8 percent year-over-year Net income was $2.5 million compared to a net loss of $9.6 million in the prior year period Adjusted EBITDA1 was $9.6 million compared to $2.0 million in the prior year period 1 Adjusted EBITDA is a non-GAAP measure. Please see Slide 12 for a reconciliation of Adjusted EBITDA to the most directly comparable GAAP measure.
Vision To expand the curative power of radiation therapy to improve as many lives as possible Mission To think, act, and execute beyond expectations every day to deliver better, safer radiation therapy solutions and help patients get back to living their lives, faster
Customer and Patient Focused Priorities Advance Care by providing solutions that address the biggest pain points in RT Drive Patient Access to radiotherapy treatments in developed and high potential underserved markets Delight Customers by ensuring high operational performance so no patient is rescheduled Hope Confidence Conquer Cancer by Closing the Gaps to Care
China Business Progress 54% YOY revenue growth driven by both Type A and B markets 16% growth in new installed base customers YOY NMPA approved the CyberKnife® S7™ and Radixact® SynC Systems 10 points share gain in CY 20241 1st 100 patients completed treatment with the Tomo® C System 1 Based on total sales in RMB. Estimated based on publicly available information from official China government procurement websites and third party market research.
China Margin Impact – Tomo® C System Due to JV accounting rules, 49% of total margin is deferred upon shipment to the JV and margin is released when the JV ships the system to the customer Deferred margin is reflected on the Balance Sheet under Assets as “Investment in JV” Net release of $3.3 million in Q2 is $2 million higher than anticipated due to earlier JV shipments to end customer Expecting full year FY25 release to be approx. $4 million 1 Adjusted EBITDA is a non-GAAP measure. Please see Slide 12, 13, 14 and 16 for a reconciliation of Adjusted EBITDA to the most directly comparable GAAP measure. 2 Gross Margin % (Excl China Margin Impact) is a non-GAAP measure. Please see Slides 17, 18 and 19 for a reconciliation of Gross Margin % (Excl China Margin Impact) to the most directly comparable GAAP measure. 1 1 1 1 2
Q2’FY25 and 1H’FY25 Financials Strong financial performance KEY FINANCIAL METRICS Highlights Robust orders with book-to-bill ratio of 1.3 Strong product revenue growth driven by China, APAC and Japan, and the CyberKnife® System product line Deferred margin release related to the higher than anticipated volume of Tomo® C Systems delivered to the end customer Raising FY25 full year revenue and adjusted EBITDA1 guidance $M Q2 Y/Y 1H Y/Y Q2 Y/Y XFX2 1H Y/Y XFX2 Revenues $116.2M 8% 8% $217.7M 3% 3% Product $61.2M 19% 20% $109.6M 4% 5% Service $55.0M (1%) (2%) $108.2M 2% 2% Op. Expenses $37.2M (7%) $73.8M (4%) Adj. EBITDA1 $9.6M 380% $12.8M 50% 1 Adjusted EBITDA is a non-GAAP measure. Please see Slides 12 and 13 for a reconciliation of Adjusted EBITDA to the most directly comparable GAAP measure. 2 Percentages shown on a constant currency basis (non-GAAP) to facilitate period-to-period comparisons without regard to the impact of foreign currency exchange rate fluctuations. Accuray calculates the constant currency amounts by translating local currency amounts in the current period using the same foreign translation rate used in the prior period being compared against rather than the actual exchange rate in effect during the current period.
Raising FY25 Guidance Revenue Adjusted EBITDA1 Previous Guidance Range $28M - $30M +42% - 52% 1 Adjusted EBITDA is a non-GAAP measure. Please see Slide 15 for a reconciliation of Adjusted EBITDA to the most directly comparable GAAP measure. $ in millions % = YoY Growth $462M - $472M +3.5% - 6% Revised Guidance Range $28.5M - $31M +45% - 57% $463M - $475M +4% - 6%
FY2025 Fiscal Focused Priorities Outpace the Market and Grow Customer Base Expand Service and Solutions Recurring Revenue Improve Profitability and Operational Excellence Strengthen Balance Sheet and Cash Flow
Thank you
$K GAAP net income (loss) Stock-based compensation Interest expense, net Restructuring charges Depreciation and amortization Three Months Ended December 31, Three Months Ended December 31, 2023 2024 $ $ 2,537 1,513 2,284 2,605 0 0 (9,621) 1,546 2,314 2,713 2,633 1,545 ERP and ERP related expenditures 695 878 GAAP to Adjusted EBITDA Q2 FY’25 and Q2 FY’24 Reconciliation of Net Income (Loss) to Adjusted Earnings Before Interest, Taxes, Depreciation, Amortization and Stock-Based Compensation (Adjusted EBITDA) Adjusted EBITDA $ $ 9,634 2,008 Provision for income taxes
$K GAAP net income (loss) Stock-based compensation Interest expense, net Restructuring charges Depreciation and amortization Six Months Ended December 31, Six Months Ended December 31, 2023 2024 $ $ (1,417) 2,977 4,638 5,257 0 0 (12,590) 2,797 4,706 5,341 2,633 2,815 ERP and ERP related expenditures 1,320 2,810 GAAP to Adjusted EBITDA 1H FY’25 and 1H FY’24 Reconciliation of Net Income (Loss) to Adjusted Earnings Before Interest, Taxes, Depreciation, Amortization and Stock-Based Compensation (Adjusted EBITDA) Adjusted EBITDA $ $ 12,775 8,512 Provision for income taxes
$K GAAP net income (loss) Stock-based compensation Interest expense, net Provision for income taxes Adjusted EBITDA Depreciation and amortization Three Months Ended September 30, Three Months Ended September 30, 2023 2024 $ $ $ $ (3,954) 1,464 2,354 2,652 625 3,141 (2,969) 1,251 2,392 2,628 1,932 6,504 ERP and ERP related expenditures 0 1,270 GAAP to Adjusted EBITDA Q1 FY’25 and Q1 FY’24 Reconciliation of Net Income (Loss) to Adjusted Earnings Before Interest, Taxes, Depreciation, Amortization and Stock-Based Compensation (Adjusted EBITDA)
$K GAAP net income (loss) Stock-based compensation Interest expense, net Provision for income taxes Adjusted EBITDA Depreciation and amortization To From $ $ $ $ (4,000) 6,500 10,000 13,000 3,000 28,500 (1,500) 6,500 10,000 13,000 3,000 31,000 GAAP to Adjusted EBITDA FY’25 – Forward Looking Guidance Reconciliation of Net Income (Loss) to Adjusted Earnings Before Interest, Taxes, Depreciation, Amortization and Stock-Based Compensation (Adjusted EBITDA) Twelve Months Ended June 30, 2025
$K GAAP net income (loss) Stock-based compensation Interest expense, net Restructuring charges Depreciation and amortization Twelve Months Ended June 30, Twelve Months Ended June 30, 2023 2024 $ $ (15,545) 5,905 9,483 10,676 2,633 3,725 (9,280) 4,527 10,053 10,340 2,738 2,492 ERP and ERP related expenditures 2,815 3,078 GAAP to Adjusted EBITDA FY2024 and FY2023 Reconciliation of Net Income (Loss) to Adjusted Earnings Before Interest, Taxes, Depreciation, Amortization and Stock-Based Compensation (Adjusted EBITDA) Adjusted EBITDA $ $ 19,692 23,948 Provision for income taxes
$K Total Net Revenue Gross Profit TT-C China Margin Deferral Gross Margin % excl TT-C China Margin Impact Total Cost of Revenue Twelve Months Ended June 30, Twelve Months Ended June 30, 2023 2024 $ $ 446,551 (303,630) 142,921 (3,031) 32.68% 447,605 (293,645) 153,960 (1,216) 34.67% Gross Profit excl TT-C China Margin Impact 145,952 155,176 Gross Margin to Gross Margin Excluding China Margin Impact Reconciliation of Gross margin to Gross margin excluding China Margin Impact $ $
$K Total Net Revenue Gross Profit TT-C China Margin (Deferral)/Release Gross Margin % excl TT-C China Margin Impact Total Cost of Revenue Three Months Ended December 31, Six Months Ended December 31, 2024 2024 $ $ 116,174 (74,282) 41,892 3,314 33.21% 217,719 (141,358) 76,361 1,321 34.47% Gross Profit excl TT-C China Margin Impact 38,578 75,040 Gross Margin to Gross Margin Excluding China Margin Impact Reconciliation of Gross margin to Gross margin excluding China Margin Impact $ $
$K Total Net Revenue Gross Profit TT-C China Margin Deferral Gross Margin % excl TT-C China Margin Impact Total Cost of Revenue Three Months Ended September 30, 2024 $ 101,545 (67,076) 34,469 (1,993) 35.91% Gross Profit excl TT-C China Margin Impact 36,462 Gross Margin to Gross Margin Excluding China Margin Impact Reconciliation of Gross margin to Gross margin excluding China Margin Impact $